German drugmaker Boehringer Ingelheim is considering the sale of its U.S. generics unit Roxane Labs for as much as 2 billion euros ($2.36 billion), Bloomberg said, citing people with knowledge of the matter.
Roxane Labs
Breaking News
Subscribe to VCpost newsletter
Most Popular
- China Hits 2 U.S. Defense Companies With Sanctions For Selling Military Weapons to Taiwan
- 940,000 Taxpayers May Receive Extra $932 Tax Refunds From IRS; Here's Why!
- American Airlines Pilots Union Issues Urgent Safety Alert Over Maintenance Issues
- Innocent Female Uber Driver, 61, Shot Dead by 81-Year-Old Ohio Man Who Was Targeted by Scammers
- Google Starts Removing Links to California News Websites in Response to Journalism Preservation Act
- Customers Rush into 99 Cents Only Stores in California Ahead of Closures
- Donald Trump Urges His Followers to Support Truth Social as Its Parent Company’s Stock Continues to Dive
- Spirit Airlines Staff at Florida Airport Filmed Cursing a 'Karen' Passenger After Moaning About Her Flight
